A pH-dependent anti-CD47 antibody that selectively targets solid tumors and improves therapeutic efficacy and safety.
Yulu LiJuan LiuWei ChenWei WangFang YangXiming LiuYao ShengKaixin DuMiaomiao HeXueyuan LyuHuiyu LiLinlin ZhaoZhizhong WeiFengchao WangSanduo ZhengJianhua SuiPublished in: Journal of hematology & oncology (2023)
Our study illustrates that the development of a tumor-selective, pH-dependent anti-CD47 antibody safely confers strong therapeutic effects against solid tumors, thus providing a promising therapeutic strategy to overcome the challenges of anti-CD47 therapy.